亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Adjuvant Transarterial Chemoembolization With Sorafenib for Portal Vein Tumor Thrombus

医学 索拉非尼 放射科 肝细胞癌 外科 临床终点 随机对照试验 内科学
作者
Zhenwei Peng,Wenzhe Fan,Zelong Liu,Han Xiao,Jian Wu,Rong Tang,Jianfei Tu,Liangliang Qiao,Fuxi Huang,Wenxuan Xie,Wenquan Zhuang,Wenbo Guo,Shaoqiang Li,Yunpeng Hua,Shunli Shen,Qiang He,Dongming Li,Jiaping Li,Ming Kuang
出处
期刊:JAMA Surgery [American Medical Association]
卷期号:159 (6): 616-616 被引量:15
标识
DOI:10.1001/jamasurg.2024.0506
摘要

Importance: Certain patients with hepatocellular carcinoma with portal vein tumor thrombus could benefit from surgical resection, and postoperative adjuvant therapy may lower the incidence of tumor recurrence. Objective: To compare the efficacy and safety of sorafenib plus transarterial chemoembolization vs sorafenib alone as postoperative adjuvant therapy for patients with hepatocellular carcinoma with portal vein tumor thrombus. Design, Setting, and Participants: This was a phase 3, multicenter, randomized clinical trial conducted in 5 hospitals in China. A total of 158 patients were enrolled and randomized from October 2019 to March 2022, with a median follow-up of 28.4 months. Portal vein tumor thrombus was graded by the Cheng classification. Eligible patients with hepatocellular carcinoma with Cheng grade I to III portal vein tumor thrombus (ie, involving segmental or sectoral branches, right- or left-side branch, or main trunk of portal vein) were included. Interventions: Patients were randomly assigned 1:1 to receive transarterial chemoembolization with sorafenib or sorafenib alone as postoperative adjuvant therapy. Sorafenib treatment was started within 3 days after randomization, with an initial dose of 400 mg orally twice a day. In the transarterial chemoembolization with sorafenib group, transarterial chemoembolization was performed 1 day after the first administration of sorafenib. Main Outcomes and Measures: The primary end point was recurrence-free survival. Efficacy was assessed in the intention-to-treat population and safety was assessed in patients who received at least 1 dose of study treatment. Results: Of 158 patients included, the median (IQR) age was 54 (43-61) years, and 140 (88.6%) patients were male. The median (IQR) recurrence-free survival was significantly longer in the transarterial chemoembolization with sorafenib group (16.8 [12.0-NA] vs 12.6 [7.8-18.1] months; hazard ratio [HR], 0.57; 95% CI, 0.39-0.83; P = .002). The median (IQR) overall survival was also significantly longer with transarterial chemoembolization with sorafenib than with sorafenib alone (30.4 [20.6-NA] vs 22.5 [15.4-NA] months; HR, 0.57; 95% CI, 0.36-0.91; P = .02). The most common grade 3/4 adverse event was hand-foot syndrome (23 of 79 patients in the transarterial chemoembolization with sorafenib group [29.1%] vs 24 of 79 patients in the sorafenib alone group [30.4%]). There were no treatment-related deaths in either group. The transarterial chemoembolization with sorafenib group did not show additional toxicity compared with the sorafenib monotherapy group. Conclusion and Relevance: In this study, the combination of sorafenib and transarterial chemoembolization as postoperative adjuvant therapy in patients with hepatocellular carcinoma with portal vein tumor thrombus resulted in longer recurrence-free survival and overall survival than sorafenib alone and was well tolerated. Trial Registration: ClinicalTrials.gov Identifier: NCT04143191.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
传奇3的应助被晚风采纳,获得10
2秒前
4秒前
4秒前
5秒前
Sarah发布了新的文献求助10
7秒前
biubiu发布了新的文献求助10
8秒前
loquatautumn完成签到 ,获得积分10
9秒前
香蕉觅云的应助被leo采纳,获得10
10秒前
10秒前
晚风发布了新的文献求助10
17秒前
萧雨墨发布了新的文献求助10
17秒前
24秒前
elfriede完成签到 ,获得积分10
30秒前
32秒前
34秒前
35秒前
123发布了新的文献求助10
36秒前
小蘑菇的应助被biubiu采纳,获得10
40秒前
懵懂的念波完成签到,获得积分10
41秒前
英俊的铭的应助被123采纳,获得10
44秒前
50秒前
领导范儿的应助被晚风采纳,获得10
53秒前
55秒前
DDDL发布了新的文献求助10
56秒前
leo发布了新的文献求助10
58秒前
1分钟前
1分钟前
晚风发布了新的文献求助10
1分钟前
CAOHOU的应助被白华苍松采纳,获得10
1分钟前
萧雨墨发布了新的文献求助10
1分钟前
1分钟前
1分钟前
1分钟前
fantasy的应助被科研通管家采纳,获得10
1分钟前
1分钟前
leo完成签到,获得积分10
1分钟前
1分钟前
amiee发布了新的文献求助10
1分钟前
1分钟前
wuyp发布了新的文献求助10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190078
求助须知:如何正确求助?哪些是违规求助? 9577216
关于积分的说明 21851985
捐赠科研通 7788239
什么是DOI,文献DOI怎么找? 3436236
关于科研通互助平台的介绍 2559951
邀请新用户注册赠送积分活动 2482818